JP2010540648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540648A5 JP2010540648A5 JP2010528062A JP2010528062A JP2010540648A5 JP 2010540648 A5 JP2010540648 A5 JP 2010540648A5 JP 2010528062 A JP2010528062 A JP 2010528062A JP 2010528062 A JP2010528062 A JP 2010528062A JP 2010540648 A5 JP2010540648 A5 JP 2010540648A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- opioid antagonist
- constipation
- gastrointestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 38
- 239000003401 opiate antagonist Substances 0.000 claims 16
- 206010010774 Constipation Diseases 0.000 claims 8
- -1 morphinan compound Chemical class 0.000 claims 7
- 231100000486 side effect Toxicity 0.000 claims 7
- 230000002496 gastric Effects 0.000 claims 6
- 206010028813 Nausea Diseases 0.000 claims 5
- 206010047700 Vomiting Diseases 0.000 claims 4
- 230000002093 peripheral Effects 0.000 claims 4
- JVLBPIPGETUEET-WIXLDOGYSA-O (3R,4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical group C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 claims 3
- JVLBPIPGETUEET-UGTAXJHQSA-O (3S,4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound C([N@@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-UGTAXJHQSA-O 0.000 claims 3
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims 3
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims 3
- DQCKKXVULJGBQN-XFWGSAIBSA-N Naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 3
- 229960003086 Naltrexone Drugs 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- 239000003467 chloride channel stimulating agent Substances 0.000 claims 3
- 230000011987 methylation Effects 0.000 claims 3
- 238000007069 methylation reaction Methods 0.000 claims 3
- 229960002921 methylnaltrexone Drugs 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 150000003839 salts Chemical group 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- HJDWPCLBBHHTIG-NNJWZEOZSA-O (4R,7S,7aR,12bS)-3-methyl-3-prop-2-enyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7,9-diol Chemical compound O([C@H]1[C@H](C=CC23)O)C4=C5[C@@]12CC[N+](C)(CC=C)[C@@H]3CC5=CC=C4O HJDWPCLBBHHTIG-NNJWZEOZSA-O 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 2
- 206010000060 Abdominal distension Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 206010071275 Functional gastrointestinal disease Diseases 0.000 claims 2
- WGFOBBZOWHGYQH-MXHNKVEKSA-N Lubiprostone Chemical compound O1[C@](C(F)(F)CCCC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 WGFOBBZOWHGYQH-MXHNKVEKSA-N 0.000 claims 2
- 229960000345 Lubiprostone Drugs 0.000 claims 2
- 230000001684 chronic Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 201000008286 diarrhea Diseases 0.000 claims 2
- 201000006549 dyspepsia Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000002618 kappa opiate receptor antagonist Substances 0.000 claims 2
- 239000002623 mu opiate receptor antagonist Substances 0.000 claims 2
- 210000001072 Colon Anatomy 0.000 claims 1
- 208000009471 Gastroesophageal Reflux Diseases 0.000 claims 1
- 206010061173 Gastrointestinal motility disease Diseases 0.000 claims 1
- 206010017885 Gastrooesophageal reflux disease Diseases 0.000 claims 1
- 102000004310 Ion Channels Human genes 0.000 claims 1
- 108090000862 Ion Channels Proteins 0.000 claims 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N Naloxone Chemical group O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 1
- 229960004127 Naloxone Drugs 0.000 claims 1
- 206010054048 Postoperative ileus Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 201000007637 bowel dysfunction Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000002183 duodenal Effects 0.000 claims 1
- 201000006860 gastroesophageal reflux disease Diseases 0.000 claims 1
- 201000002146 gastrointestinal system disease Diseases 0.000 claims 1
- 201000005081 intestinal pseudo-obstruction Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000003364 opioid Effects 0.000 claims 1
- 230000003405 preventing Effects 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97665207P | 2007-10-01 | 2007-10-01 | |
| US60/976,652 | 2007-10-01 | ||
| PCT/US2008/078229 WO2009045985A1 (en) | 2007-10-01 | 2008-09-30 | Treatment of drug-induced nausea with opioid antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014208895A Division JP2015028074A (ja) | 2007-10-01 | 2014-10-10 | 薬剤誘発性吐き気のオピオイド拮抗薬による治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010540648A JP2010540648A (ja) | 2010-12-24 |
| JP2010540648A5 true JP2010540648A5 (hr) | 2012-11-22 |
| JP5905198B2 JP5905198B2 (ja) | 2016-04-20 |
Family
ID=40526634
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528062A Expired - Fee Related JP5905198B2 (ja) | 2007-10-01 | 2008-09-30 | 薬剤誘発性吐き気のオピオイド拮抗薬による治療 |
| JP2014208895A Pending JP2015028074A (ja) | 2007-10-01 | 2014-10-10 | 薬剤誘発性吐き気のオピオイド拮抗薬による治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014208895A Pending JP2015028074A (ja) | 2007-10-01 | 2014-10-10 | 薬剤誘発性吐き気のオピオイド拮抗薬による治療 |
Country Status (2)
| Country | Link |
|---|---|
| JP (2) | JP5905198B2 (hr) |
| WO (1) | WO2009045985A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006096626A2 (en) | 2005-03-07 | 2006-09-14 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| JP2014515004A (ja) * | 2011-04-27 | 2014-06-26 | スキャンポ・アーゲー | イオン輸送体の調節方法 |
| CN108685929A (zh) * | 2012-04-23 | 2018-10-23 | 苏坎波公司 | 用于治疗具有腹泻的肠易激综合征的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4673679A (en) * | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
| MXPA02005335A (es) * | 1999-11-29 | 2003-01-28 | Adolor Corp | Metodos y composiciones novedosos que incluyen opioides y antagonistas de los mismos. |
| WO2004091622A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome |
| AU2004229463B2 (en) * | 2003-04-08 | 2010-07-22 | Progenics Pharmaceuticals. Inc. | Pharmaceutical formulations containing methylnaltrexone |
| CA2529307C (en) * | 2003-06-13 | 2013-12-24 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7494979B2 (en) * | 2003-06-13 | 2009-02-24 | Ironwood Pharmaceuticals, Inc. | Method for treating congestive heart failure and other disorders |
| US20060063792A1 (en) * | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
| AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| CN101311170B (zh) * | 2007-05-25 | 2010-09-15 | 中国中化股份有限公司 | 取代嘧啶醚类化合物及其应用 |
-
2008
- 2008-09-30 WO PCT/US2008/078229 patent/WO2009045985A1/en active Application Filing
- 2008-09-30 JP JP2010528062A patent/JP5905198B2/ja not_active Expired - Fee Related
-
2014
- 2014-10-10 JP JP2014208895A patent/JP2015028074A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010540648A5 (hr) | ||
| CA2235375C (en) | Production of analgesic synergy by co-administration of sub-analgesic doses of a .mu. opioid agonist and a .kappa.-2 opioid agonist | |
| UA93543C2 (ru) | Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон | |
| WO2007005716A2 (en) | Methods of treatment and compositions for use thereof | |
| AU2016244249B2 (en) | Systems and methods for treating an opioid-induced adverse pharmacodynamic response | |
| JP2015514743A5 (hr) | ||
| WO2006020930A3 (en) | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | |
| EA200870449A1 (ru) | Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами | |
| CA2569742A1 (en) | Opioids for the treatment of the restless leg syndrome | |
| JP2011137020A5 (hr) | ||
| MXPA05003104A (es) | Hidromorfonas n-sustituidas y uso de las mismas. | |
| HRP20100373T4 (hr) | Upotreba kombinacije morfina s najmanje jednim opijatnim antagonistom u liječenju ovisnosti o opijatima i u sprječavanju neoralne zloupotrebe opijata kod ovisnika opijatima | |
| CN102711759A (zh) | 胆道疾病的治疗或预防药 | |
| WO2006053012A3 (en) | Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria | |
| US20120245193A1 (en) | PERIPHERIALLY ACTING μ OPIOID ANTAGONISTS | |
| JP2013505260A5 (hr) | ||
| US10226457B2 (en) | Systems and methods for treating an opioid-induced adverse pharmacodynamic response | |
| JP5797655B2 (ja) | 消化管障害のためのオピオイド受容体アンタゴニストの使用 | |
| RU2003135201A (ru) | Применение антагониста опиоидов налтрексона для предупреждения и контроля побочных воздействий, вызванных опиоидами | |
| Sandham et al. | Recent advances in gastrointestinal prokinetic agents | |
| Beattie et al. | TD-1211, a potent and peripherally-selective μ-opioid receptor antagonist | |
| Galloway et al. | Opioid-induced bowel dysfunction. | |
| TW200512204A (en) | A method of treating breast cancer with androgen receptor antagonists | |
| WO2016193456A3 (en) | Opioid receptor antagonist for use in treating patients with severe constipation |